Author Bio
Keith began writing for the Fool in 2012 and focuses primarily on healthcare investing topics. His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries.
Follow @keithspeights
What happened
Shares of
Syndax Pharmaceuticals (NASDAQ:SNDX) were sinking 28% as of 11:32 a.m. EDT on Tuesday. This big decline came after the company reported positive results from a phase 1 study evaluating SNDX-5613 in treating leukemia.
So what
Normally, when a biotech stock plunges after announcing clinical results, it s because the news was really bad. However, that didn t seem to be the case for Syndax at least on the surface.
(CRSP), (KALV) - Why Crispr, KalVista And Syndax Are Moving Today
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.